Allergan Bolsters Botox Business With Record-Setting Korean Deal
This article was originally published in PharmAsia News
In the largest licensing deal ever signed by a Korean health care company, Medy-Tox teams up with Allergan for next-generation neurotoxin products that could help Allergan protect its lead as new competitors like J&J look to enter the market.
You may also be interested in...
The Irvine, Calif.-based company reported full-year results on Feb. 5 that highlighted the growth of its Botox business to several new indications.
Allergan partnered with MAP in 2011 for rights to commercialize Levadex for acute migraine in North America, but now will control 100% of the product’s revenue, creating a complementary product to Botox in chronic migraine. Levadex has an April 15 PDUFA date at FDA.
The FDA approval for idiopathic OAB follows a narrower indication for OAB related to neurological diseases such as multiple sclerosis or spinal cord injury.